First‐in‐man allopregnanolone use in super‐refractory status epilepticus

Super‐refractory status epilepticus (SRSE) is associated with high morbidity and mortality. Treatment of SRSE is complicated by progressive cortical hyperexcitability believed to result in part from synaptic GABA receptor internalization and desensitization. Allopregnanolone, a neurosteroid that pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaitkevicius, Henrikas, Husain, Aatif M., Rosenthal, Eric S., Rosand, Jonathan, Bobb, Wendell, Reddy, Kiran, Rogawski, Michael A., Cole, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454395/
https://www.ncbi.nlm.nih.gov/pubmed/28589168
http://dx.doi.org/10.1002/acn3.408
Descripción
Sumario:Super‐refractory status epilepticus (SRSE) is associated with high morbidity and mortality. Treatment of SRSE is complicated by progressive cortical hyperexcitability believed to result in part from synaptic GABA receptor internalization and desensitization. Allopregnanolone, a neurosteroid that positively modulates synaptic and extrasynaptic GABA(A) receptors, has been proposed as a novel treatment. We describe the first two patients with SRSE who were each successfully treated with a 120‐h continuous infusion of allopregnanolone. Both patients recovered from prolonged SRSE with good cognitive outcomes.

Ejemplares similares